Sanofi-Aventis's oral MS candidate shows promise in combination
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's oral multiple sclerosis drug candidate teriflunomide produced a significant improvement in disease activity after one year as measured by the number of gadolinium enhancing T1 lesions compared with placebo, in patients with relapsing disease also taking interferon-beta, in a Phase II study.